Global Pharma, Biotech and Diagnostics Joint Venture Partnering Terms and Agreements 2012-2018 - ResearchAndMarkets.com

DUBLIN--()--The "Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018" report has been added to ResearchAndMarkets.com's offering.

The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report provides comprehensive understanding and unprecedented access to the joint venture deals and agreements entered into by the worlds leading life science companies.

This report provides details of the latest joint venture agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date, the report provides details of joint venture agreements from 2012.

There is an increasing willingness for parties to enter joint venture deals; such deals enable both parties to benefit from the upside of a big product win, whereas traditional licensing deals forfeit upside for near term upfront, milestone and royalty payments.

Joint venture partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal.

Another reason for joint venture deals is the joint origin of a project. Drug development projects often require various scientific and technological novelties that stem from different companies. If both companies contributed to the origination of the project, then both have from the beginning a stake in the project.

The report provides a detailed understanding and analysis of how and why companies enter joint venture deals.

In conclusion, this report provides everything a prospective dealmaker needs to know about Joint venture alliances.

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in joint venture partnerships

Chapter 3 - Overview of joint venture deal structure

Chapter 4 - Leading joint venture deals

Chapter 5 - Top 50 most active active joint venture dealmakers

Chapter 6 - Joint venture deals including contracts directory

For more information about this report visit https://www.researchandmarkets.com/research/txtw8p/global_pharma?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Biotechnology, Pharmaceuticals, Diagnostics

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Biotechnology, Pharmaceuticals, Diagnostics